BioSpace News Archive

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Adagene, Inc. announced that Peter Luo, Ph.D., Co-founder and Chief Executive Officer, will present an overview of the company at the 38th Annual J.P. Morgan Healthcare Conference.

NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation nanotechnology platform, announced that industry veterans Han Myint, MD, and John Trainer, MBA, have been appointed as the Company’s Chief Medical Officer and Chief Financial Officer, respectively.

ACE1702 is a potential off-the-shelf cell therapy developed using Acepodia’s Antibody-Cell Conjugation technology

Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease

On track to submit IND application for lead candidate, NTLA-2001 for transthyretin amyloidosis, in mid-2020 and dose first patients in 2H 2020

Encompass Health Corp. announced it will report results for its fourth quarter ended Dec. 31, 2019, after the market closes on Feb. 6, 2020. The Company will host an investor conference call at 9 a.m. ET on Feb. 7, 2020, to discuss its results..

Emergex Vaccines Holding Limited, a biotechnology company developing set-point vaccines to prevent serious infectious diseases, announced that it has secured over US$11 million in a Series A round.

WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.

Trial to assess AMO-02 in treatment of congenital myotonic dystrophy to begin patient enrollment in early 2020.